Scientific Program

Filter Results:

Show Only CME Accredited Sessions

  • +

    IS07 - Symposium by Daiichi Sankyo: Targeting Her Pathways In Advanced NSCLC: Emerging Concepts And Future Opportunities (Not IASLC CME Accredited)

    • Type: Industry Symposia & Workshops
    • Track:
  • +

    IS08 - Symposium by Pfizer: EGFR+ and ALK+ NSCLC: More Options, Right Choices (Not IASLC CME Accredited)

    • Type: Industry Symposia & Workshops
    • Track:
  • +

    PL01 - New Questions with Imaginative Answers

    • Type: Plenary Session
    • Track: Advanced NSCLC
    • +

      PL01.01 - Tumor-Agnostic Biologically Driven Treatments: An Endless Dream?

      08:15 - 08:30  |  Presenting Author(s): Robert C. Doebele

      • Abstract

      Loading...

    • +

      PL01.02 - The Evolution of Tissue Testing for Immunotherapy - Where Next?

      08:30 - 08:45  |  Presenting Author(s): Keith Kerr

      • Abstract

      Loading...

    • +

      PL01.03 - Will the Immunotherapy with Newer Biomarkers, Combination Therapy or New Technology Eventually Cure Lung Cancer?

      08:45 - 09:00  |  Presenting Author(s): Tetsuya Mitsudomi

      • Abstract

      Loading...

    • +

      PL01.04 - Artificial Intelligence, Big Data and Lung Cancer: Ready to Implement?

      09:00 - 09:15  |  Presenting Author(s): Hugo Aerts

      • Abstract

      Loading...

  • +

    PR02 - Press Conference

    • Type: Press Conference
    • Track: Immuno-oncology
    • +

      PR02.01 - Summary of Day's Plenary

      09:45 - 09:50  |  Presenting Author(s): Enriqueta Felip

      • Abstract

      Abstract not provided

    • +

      PR02.02 - Phase 1 Study of Safety, Tolerability, P­­K and Efficacy of AMG 510, a Novel KRAS G12C Inhibitor, Evaluated in NSCLC

      09:50 - 09:57  |  Presenting Author(s): Ramaswamy Govindan

      • Abstract

      Abstract not provided

    • +

      PR02.03 - Announcement of JTO Clinical and Research Reports

      09:57 - 10:02  |  Presenting Author(s): Alex A Adjei

      • Abstract

      Abstract not provided

    • +

      PR02.04 - Mutations Associated with Sensitivity or Resistance to Immunotherapy in mNSCLC: Analysis from the MYSTIC Trial

      10:02 - 10:09  |  Presenting Author(s): Naiyer A Rizvi

      • Abstract

      Abstract not provided

    • +

      PR02.05 - CheckMate 817: First-Line Nivolumab + Ipilimumab in Patients with ECOG PS 2 and Other Special Populations with Advanced NSCLC

      10:09 - 10:16  |  Presenting Author(s): Fabrice Barlesi

      • Abstract

      Abstract not provided

    • +

      PR02.06 - KEYNOTE-021: TMB and Outcomes for Carboplatin and Pemetrexed With or Without Pembrolizumab for Nonsquamous NSCLC

      10:16 - 10:23  |  Presenting Author(s): Corey Jay Langer

      • Abstract

      Abstract not provided

    • +

      PR02.07 - Evaluation of TMB in KEYNOTE-189: Pembrolizumab Plus Chemotherapy vs Placebo Plus Chemotherapy for Nonsquamous NSCLC

      10:23 - 10:30  |  Presenting Author(s): Marina Chiara Garassino

      • Abstract

      Abstract not provided

  • +

    ES01 - What Is the Role of Chemotherapy in the Era of Immunotherapy in Advanced NSCLC?

    • Type: Educational Session
    • Track: Advanced NSCLC
    • +

      ES01.01 - Chemotherapy is Strictly Additive to Immunotherapy

      10:30 - 10:45  |  Presenting Author(s): Johan Vansteenkiste  |  Author(s): Els Wauters

      • Abstract

      Loading...

    • +

      ES01.02 - Chemotherapy Enhances the Efficacy of Immunotherapy

      10:45 - 11:00  |  Presenting Author(s): Natasha B Leighl

      • Abstract

      Loading...

    • +

      ES01.03 - Chemotherapy Directly Targets the Immune System to Improve Efficacy 

      11:00 - 11:15  |  Presenting Author(s): Daniel SW Tan

      • Abstract

      Loading...

    • +

      ES01.04 - Immunotherapy, Radiotherapy and Chemotherapy Combination: A Potential New Standard?

      11:15 - 11:30  |  Presenting Author(s): Maurice Perol

      • Abstract

      Loading...

    • +

      ES01.05 - Future of Dual Anti-CTLA4 and PD1/PDL1 Blockade

      11:30 - 11:45  |  Presenting Author(s): David R Spigel

      • Abstract

      Abstract not provided

    • +

      ES01.06 - Q&A

      11:45 - 12:00

      • Abstract

      Abstract not provided

  • +

    ES02 - Management of Oncogene Addicted Patients with Stage III NSCLC

    • Type: Educational Session
    • Track: Treatment of Locoregional Disease - NSCLC
    • +

      ES02.01 - Biomarker Testing in LA Disease

      10:30 - 10:45  |  Presenting Author(s): Helena A Yu

      • Abstract

      Loading...

    • +

      ES02.02 - Management of EGFR LA Disease

      10:45 - 11:00  |  Presenting Author(s): Keunchil Park

      • Abstract

      Loading...

    • +

      ES02.03 - Management of Other Non EGFR Oncogene Addicted Tumors

      11:00 - 11:15  |  Presenting Author(s): Charu Aggarwal

      • Abstract

      Loading...

    • +

      ES02.04 - Concurrent, Sequential and Combination Immunotherapy Regimens in LA-NSCLC

      11:15 - 11:30  |  Presenting Author(s): Mariano Provencio

      • Abstract

      Loading...

    • +

      ES02.05 - Q&A

      11:30 - 12:00

      • Abstract

      Abstract not provided

  • +

    ES03 - BAP-1 and Other Novel Molecular and Metabolic Targets in Mesothelioma

    • Type: Educational Session
    • Track: Mesothelioma
    • +

      ES03.01 - Targeting Altered microRNA Expression in Mesothelioma

      10:30 - 10:40  |  Presenting Author(s): Glen Reid

      • Abstract

      Loading...

    • +

      ES03.02 - Targeting CDKN2A in Mesothelioma

      10:40 - 10:50  |  Presenting Author(s): Dean Anthony Fennell

      • Abstract

      Loading...

    • +

      ES03.03 - Targeting NF2 in Mesothelioma

      10:50 - 11:00  |  Presenting Author(s): Yoshitaka Sekido

      • Abstract

      Loading...

    • +

      ES03.04 - Pegargiminase to Treat Mesothelioma

      11:00 - 11:10  |  Presenting Author(s): Peter Szlosarek

      • Abstract

      Loading...

    • +

      ES03.05 - Inherited Predisposition to Mesothelioma, Biological and Clinical Differences with Sporadic Mesothelioma

      11:10 - 11:20  |  Presenting Author(s): Jane E. Churpek

      • Abstract

      Loading...

    • +

      ES03.06 - Q&A

      11:20 - 12:00

      • Abstract

      Abstract not provided

  • +

    ES04 - Multimodality Management of Small Cell and Neuroendocrine Cancers

    • Type: Educational Session
    • Track: Small Cell Lung Cancer/NET
    • +

      ES04.01 - Update in Systemic Treatment of SCLC

      10:30 - 10:40  |  Presenting Author(s): Sumitra Thongprasert

      • Abstract

      Loading...

    • +

      ES04.02 - Pathology Overview for Carcinoid and NE Spectrum

      10:40 - 10:50  |  Presenting Author(s): Elisabeth Brambilla

      • Abstract

      Loading...

    • +

      ES04.03 - Surgery for Early and Locally Advanced Small Cell Lung Cancer

      10:50 - 11:00  |  Presenting Author(s): Eric Lim

      • Abstract

      Abstract not provided

    • +

      ES04.04 - Role of Stereotactic Body Radiation in Early and Advanced SCLC

      11:00 - 11:10  |  Presenting Author(s): Roy Decker

      • Abstract

      Loading...

    • +

      ES04.05 - Advances in Radionuclide Treatment for Neuroendocrine Tumours

      11:10 - 11:20  |  Presenting Author(s): Angela Lamarca

      • Abstract

      Loading...

    • +

      ES04.06 - Systemic Treatment of Large Cell Neuroendocrine Cancer

      11:20 - 11:30  |  Presenting Author(s): Fiona Blackhall

      • Abstract

      Loading...

    • +

      ES04.07 - Q&A

      11:30 - 12:00

      • Abstract

      Abstract not provided

  • +

    ES05 - Joint Session GLCC/IASLC: Hot Topics for Lung Cancer Advocates

    • Type: Educational Session
    • Track: Advocacy
    • +

      Introduction/Poll

      10:30 - 10:30

      • Abstract

      Abstract not provided

    • +

      ES05.01 - Lung Cancer Survival: Progress and Challenges

      10:30 - 10:45  |  Presenting Author(s): Marianne Coutts Nicolson

      • Abstract

      Loading...

    • +

      ES05.02 - From Living Longer to Also Living Better – the Role of Communication and Interprofessional Collaboration in Metastatic Lung Cancer

      10:45 - 11:00  |  Presenting Author(s): Matthias Villalobos

      • Abstract

      Loading...

    • +

      ES05.03 - From Living Longer to Also Living Better; Managing Lung Cancer as a Chronic Disease - the Principle of Survivorship

      11:00 - 11:15  |  Presenting Author(s): Maureen Rigney

      • Abstract

      Loading...

    • +

      ES05.04 - Social Media and Lung Cancer - a Global Picture

      11:15 - 11:30  |  Presenting Author(s): Christina Sit  |  Author(s): Jesme Fox, Simon Malia

      • Abstract

      Loading...

    • +

      ES05.05 - Still Struggling for Traction - from Proving Lung Cancer Screening Works to Global Practical Implementation, Including Engagement of the Target Population

      11:30 - 11:45  |  Presenting Author(s): James L Mulshine

      • Abstract

      Loading...

    • +

      ES05.06 - Q&A/Poll

      11:45 - 12:00

      • Abstract

      Abstract not provided

  • +

    MA01 - Oligometastatic Disease

    • Type: Mini Oral Session
    • Track: Oligometastatic NSCLC